TO THE EDITOR {#s1}
=============

In a recent issue of this journal Dr. Oymak and her colleagues presented a clinically and genetically well-studied 5-year-old boy who was seen with severe microangiopathic hemolytic anemia without laboratory findings of renal involvement despite complement factor H gene mutations \[[@ref1]\].

Because of Yeneral's extensive review \[[@ref2]\] on atypical hemolytic uremic syndrome (aHUS) published recently in the Turkish Journal of Hematology, I brought it to readers' attention that more recently some authors do not use 'aHUS', which was historically used to distinguish heterogeneous uncharacterized syndromes from Shiga toxin-related HUS, since the term lacks both specificity and suggested causes \[[@ref3]\].

Though in our patient with thrombotic thrombocytopenic purpura renal involvement was documented at the beginning but not in the last two recurrences, neither serum nor urinary findings indicated kidney involvement \[[@ref4]\].

Although the discussions of Dr. Oymak et al. are well taken, the term 'microangiopathic hemolytic anemia' is covering the syndrome to a large extent as suggested by George and Nester \[[@ref5]\].
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